As researchers began to piece together DNA from different sources, they themselves warned of potential risks. But Cambridge residents demanded that the decision not be left to the scientists alone. The 1976 clash helped shape the regulation of biotechnology and continues to resonate in the era of gene editing, artificial intelligence and synthetic biology.
America in Test Tube | Chapter 7 of 8
This article is part of the “America in Test Tube” series to mark the 250th anniversary of the United States, which examines how the world’s greatest scientific power was built – and what happens when scientific discoveries give researchers and companies power that the law and society still don’t know how to regulate.
Previous episode: The dark side of scientific progress – the bomb, eugenics, and erased knowledge | for all episodes of the series
In the previous installment of the “America in Test Tube” series, we saw how scientific knowledge can give the state and institutions tremendous power – to build nuclear weapons, classify people, and eliminate the contributions of those who were not allowed into scientific institutions. The current installment deals with a different attempt: not only to criticize science after the fact, but to decide in advance who is allowed to participate in setting its boundaries.
In the 20s, researchers learned to combine DNA fragments from different sources and introduce them into cells. The technology, known as Recombinant DNA, opened up new possibilities: producing proteins and drugs in bacteria, studying the function of genes, creating organisms with new properties, and laying the foundations for the biotech industry.Biotechnology Modern.
But the ability to transfer genetic material between organisms has also raised troubling questions. Could a genetically engineered bacterium escape from the lab? Could a gene from a virus or another organism cause unexpected harm? Do researchers understand enough about the system they are modifying? And who has the authority to decide whether the risk is acceptable?
Initially, the discussion took place mainly within the scientific community. But thenCambridge In Massachusetts, where Harvard University sought to establish a laboratory for research into recombinant DNA, residents demanded that the decision not be left to the scientists alone.
The scientists who stopped and asked if they were allowed to continue
The debate did not begin with public opposition from outside. Some of the pioneers of molecular biology themselves feared that research was advancing faster than the ability to assess its risks.
The ability to cut DNA at specific points, join together segments from different sources, and insert them into bacteria made it possible to perform experiments that were not possible before. For the first time, it was possible to create genetic combinations in the laboratory that would not necessarily occur in nature.
Some researchers have suggested temporarily halting certain types of experiments until safety rules are established. The very call by scientists to halt promising research was unusual. It expressed recognition that the question was not just whether an experiment was possible, but also whether it could be done responsibly.
In 1975, scientists, lawyers, and government officials gathered inAsilomar Conference in California to discuss the risks. They proposed a tiered set of safety measures: adapting the level of protection to the type of experiment, using closed containers and laboratories, and developing weakened bacteria that would not easily survive outside of laboratory conditions.
Asilomer has since become a symbol of the scientific community's ability to police itself. But it also revealed a limitation: Most of the participants were scientists and experts. The people who lived near the labs and who could bear the consequences of a malfunction had little say in setting the rules.
When the lab entered the city hall
In the summer of 1976, Cambridge City Hall was filled with hundreds of residents. At issue was Harvard's plan to open a recombinant DNA research laboratory in a densely populated urban area.
According to historian Luis A. Campos, the angry and colorful mayor demanded that the scientists explain why the plan had not been made public in advance. One of the signs in the crowd declared: "No recombination without representation" – There is no recombination without representation.
The play on words was intentional. The scientific concept of “recombination” – the reassembly of genetic material – was connected to the political principle that power should not be exercised without representation of the people who would be affected by it.
The meeting sometimes took on the character of a political show. Scientists felt that the complex scientific discussion was turning into a circus, while residents feared that experts were hiding experiments from them that could endanger their environment.
But behind the confrontation stood a serious question: Is the one who understands the technology also the only one who can decide whether to use it?
Expertise does not grant an exclusive right to decide
Scientists had a clear advantage. They knew how the bacteria worked, what the genetic vectors were, what safety mechanisms had been developed, and what the estimated likelihood of a malfunction was.
But the decision was not merely scientific.
The question of what is an acceptable risk also involves values. A researcher may be willing to accept a small risk to advance a promising medical treatment, while a resident living near the laboratory believes that he should not have to bear a risk he did not choose. A scientist may estimate that the chance of a malfunction is small, but the public asks what the consequences would be if it nevertheless occurred.
Science can estimate probabilities, describe mechanisms, and compare alternatives. It cannot alone decide how much risk is permissible to impose on others, who will bear responsibility, or what goals justify the risk.
On the other hand, even a decision based solely on public fear may halt useful research. Not every possible scenario is a plausible one, and not every new technology poses a threat simply because it is difficult to understand.
Therefore, the challenge is not to choose between the rule of experts and the rule of public opinion. It is to build a mechanism in which scientific expertise, public responsibility, and moral considerations meet.
Molecular biology has become political
The Cambridge debate created a new kind of politics. Until then, molecular biology had been seen by many as a purely laboratory field, far removed from debates about city government, neighborhoods, and local democracy.
Scientists were now required to attend public meetings, explain their work in non-professional language, and deal with people who did not take their authority for granted.
Even the researchers who had warned of the risks from the start had a hard time. Maxine Singer, who had been a central figure in the debate over the safety of recombinant DNA, wrote to Paul Berg that she was surprised by her unlimited capacity for anger as they both tried to deal with the public uproar. She added sarcastically that their problem was that neither of them was Thomas Jefferson—that is, they were scientists, not skilled architects of a democratic regime.
The statement reveals the difficulty: Scientists were suddenly asked to also be media figures, policy experts, and mediators between professional knowledge and public concerns.
Citizens' Committee Instead of a General Ban
The practical outcome of the confrontation was milder than the noise that accompanied it.
Cambridge did not completely ban the research. A review committee was established with the participation of citizens, whose role was to formulate rules for the studies planned in the city and examine safety measures.
This was one of the first cases in which citizens participated directly in shaping the governance of biotechnology. They did not replace the scientists or conduct the experiments, but they were given a place in the mechanism that determined the conditions under which the experiments would be conducted.
The affair shows that public oversight need not be the enemy of innovation. The rules created as a result of the debate did not eliminate the biotechnology industry in Cambridge. On the contrary: the area went on to become one of the world's largest centers for biotechnology research and companies.
It can be concluded that clear rules, transparency, and public trust may allow research to develop more stably. An industry operating without social consensus may later encounter strong opposition, bans, or a crisis of trust.
The bacteria that were designed not to survive
In parallel with the public debate, researchers have tried to make the technology safer using biology itself.
Vectors and bacteria have been developed that are designed to work in the laboratory but have difficulty surviving outside it. Campos mentions, among other things, a bacteriophage vector humorously called “lambda for the people”, and a strain of E. coli Called χ1776 – a name that deliberately alluded to the year of the American Declaration of Independence.
The idea was to create Biological containment: Not to rely solely on doors, filters, suits, and procedures, but to design an organism that is dependent on laboratory conditions and is unable to compete successfully in the natural environment.
This was a recognition that no security system is perfect. People can make mistakes, equipment can fail, and procedures can be compromised. Therefore, it is advisable to build several independent layers of protection.
The same principle continues to guide research in synthetic biology today, inGenetic Engineering and in the development of genetically modified organisms.
From fear of the germ to an entire industry
Within a few years, the discussion shifted from the question of whether to ban the research to the question of how to commercialize its results.
In 1980, the United States Supreme Court ruled in Diamond v. Chakrabarty, that a human-made genetically modified bacterium can be patented. The decision expanded the possibility of protecting biotechnological inventions with intellectual property and helped turn genetically modified organisms into commercial assets.
That same year, Genentech made the first public offering of a biotechnology company. On the same day, Paul Berg received notice that he had won the Nobel Prize for his work in the field of recombinant DNA.
The combination was symbolic: a field that began as a debate about risks and the halting of research turned within a few years into award-winning science and an industry attracting enormous capital.
Commercial success has not eliminated fundamental questions. It has added new ones: Who owns a genetically modified organism? Is it permissible to patent life? Can a company control technology developed with public funding? And how does the desire for profit influence risk assessment?
Freedom from technology and freedom to use it
The debate over biotechnology is sometimes fought between two types of freedom.
One is Freedom from risk or coercion: The right of people not to be exposed to dangerous experimentation, not to have genetic information collected about them without consent, and not to be subject to decisions by institutions or companies over which they have no control.
The second is The freedom to use technology: The right of researchers to research, of patients to receive new treatment, and of people to use biological knowledge to improve their health and lives.
The two types of freedom can conflict. A blanket ban may protect against risk, but also prevent life-saving treatment. Complete freedom for researchers and companies may accelerate innovation, but shift the risks to the public.
Campos describes the debate as part of the American democratic experiment itself: how to balance “freedom from” and “freedom to,” as technology changes the possibilities available to society.
CRISPR brought back the questions with greater force
In the 1970s, the main concern was with bacteria carrying new DNA segments. Today, technological capabilities such as CRISPR To change genes at a specific location, to edit patient cells, and sometimes also to change reproductive cells and embryos – changes that could be passed on to future generations.
The experiment in China that produced genome-edited twins illustrated what happens when a researcher moves forward without broad consent, adequate oversight, or clear medical benefit. Criticism focused not only on whether the editing was successful, but also on the fact that the experiment created genetic changes in children who could not have consented to it, while the risks were not fully known. ([Hayadan])
The example highlights a lesson from Cambridge: technical institutional approval is no substitute for public and moral debate, especially when the consequences are not limited to the participant in the experiment but may be passed on to his descendants.
There is no simple answer here either. gene editing It can be used to treat serious diseases, but it can also lead to trait selection, widening disparities, and social pressure to produce children who conform to a certain norm. These questions are no longer the internal business of biologists.
Who represents future generations?
Genetic technologies pose a problem that has no easy solution in a normal democracy: some of the people who will be affected by the decision do not yet exist.
A heritable change in the genome can be passed down for many generations. Releasing a genetically modified organism into the environment can have long-term effects on ecosystems. A genetic database built today can be used in the future in ways that cannot be predicted.
Who is qualified to speak on behalf of future generations? Scientists? Parents? Courts? Ethics committees? Parliaments?
Public decision-making does not guarantee a correct decision, but it prevents a situation in which a small group decides alone about risks imposed on others. Therefore, mechanisms are needed that integrate experts, public representatives, ethicists, lawyers, and groups that may be particularly affected.
And what about artificial intelligence?
The debate over recombinant DNA also offers a framework for non-biological technologies.
Artificial intelligence, for example, is developed primarily in companies and labs that hold knowledge and computing that is not available to the general public. Experts know how the systems work better than lawmakers and citizens, but decisions about their use affect jobs, education, health, privacy, security, and public information.
As in biotechnology in the 1970s, companies can claim that only they understand the technology and therefore only they can set the safety rules. The public can react with fear or demand that everything be stopped. Neither position is satisfactory.
The lesson from Cambridge is that the process must be initiated before the technology becomes a fait accompli. It is not enough to issue a public announcement after the system has already been built and implemented.
Public participation is not a vote on facts.
Public participation does not mean that scientific truth is determined by a vote. City residents cannot decide by majority vote that a particular bacterium cannot survive, if the evidence shows otherwise.
The public is also allowed to participate in decisions about goals, risks, liability, and compensation.
The role of scientists is to present knowledge and uncertainty honestly. The role of the public and its elected officials is to determine the values and priorities by which knowledge will be acted upon. The role of regulators is to turn principles into enforceable rules.
Each side also has an obligation to recognize its limitations. Scientists do not necessarily know how society should operate; politicians cannot change facts; and the public should not make decisions based on misleading information or deliberate fear.
From fear to trust
The Cambridge debate is not a story in which the public defeated the scientists or in which the scientists convinced the public to let them work.
It is a story about the creation of a new institution: a committee in which experts and citizens were required to learn to work together.
Ultimately, research into recombinant DNA did not stop. It gave rise to drugs, diagnostic tools, industries, and companies. But its development was accompanied by safety regulations and public debate that arose in large part because residents refused to stay out of the room.
The success of biotechnology is not proof that the concerns were unnecessary. It could be argued that the ability to continue research stemmed precisely from the fact that the concerns were taken seriously and became rules.
Responsible science is not science that avoids all risk. It is science that explains risk, allows for criticism, and does not assume that professional expertise grants exemption from democratic accountability.
More on the subject on the science website
- In the Science Committee: Oversight of research into genetically modified plants — The closest Israeli equivalent to the Cambridge story: A committee including scientists, government representatives, and public representatives oversees experiments with genetically modified plants and microorganisms, including environmental risks and commercialization.
- Bioethics Now: The Importance of Public Discourse in the Face of Advances in Medicine and Technology — About meetings open to the public intended to raise for discussion the moral questions arising from scientific advances, and about the need not to leave decisions to the experts alone.
- The politics of cloning — A review of the law prohibiting genetic intervention in Israel and the attempt to establish an updated mechanism for supervising human cloning and genetic modification in reproductive cells, instead of being satisfied with a permanent ban that does not change with science.
- The chairwoman of the science committee voted alone: The law banning cloning will become permanent — A case that illustrates the flip side of public and professional participation: a far-reaching regulatory decision made unanimously and contrary to the position of many experts.
- Noah was surprised by his office's position regarding embryo cloning — On the tension between medical benefit, public opposition, and oversight through Helsinki and bioethics committees; precisely the question of how to enable research without giving up control.
- The failure of the gene-edited baby experiment in China proves we are not ready for gene editing of human embryos — A late example of research that progressed without public consent, adequate oversight, and established medical benefit, and therefore illustrates what happens when control mechanisms fail.
